Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade F 24.85 -1.78% -0.45
ALKS closed down 1.78 percent on Friday, May 17, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ALKS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.78%
NR7 Range Contraction -1.78%
NR7-2 Range Contraction -1.78%
Inside Day Range Contraction -1.78%
Wide Bands Range Expansion -1.78%

Older signals for ALKS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Chemistry Biopharmaceutical Pain Surgery Chemotherapy Multiple Sclerosis Organic Chemistry Schizophrenia Hypertension Morphinans Neurochemistry Nausea Ii Diabetes Obsessive Compulsive Disorder AIDS Angina Depressive Disorder Opioid Antagonists Pharmaceutical Wholesalers Treatment Of Multiple Sclerosis Atypical Antipsychotics Opioid Induced Constipation Renal Transplant
Is ALKS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 51.7
52 Week Low 24.81
Average Volume 1,124,582
200-Day Moving Average 36.1249
50-Day Moving Average 32.2482
20-Day Moving Average 28.635
10-Day Moving Average 26.292
Average True Range 1.1416
ADX 43.75
+DI 8.1302
-DI 37.6157
Chandelier Exit (Long, 3 ATRs ) 31.5452
Chandelier Exit (Short, 3 ATRs ) 28.2348
Upper Bollinger Band 34.5443
Lower Bollinger Band 22.7257
Percent B (%b) 0.18
BandWidth 41.273267
MACD Line -2.2396
MACD Signal Line -1.9868
MACD Histogram -0.2528
Fundamentals Value
Market Cap 3.82 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -19.26
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.77
Resistance 3 (R3) 25.85 25.64 25.61
Resistance 2 (R2) 25.64 25.40 25.59 25.56
Resistance 1 (R1) 25.24 25.26 25.14 25.16 25.51
Pivot Point 25.03 25.03 24.97 24.98 25.03
Support 1 (S1) 24.63 24.79 24.53 24.55 24.19
Support 2 (S2) 24.42 24.65 24.37 24.14
Support 3 (S3) 24.02 24.42 24.09
Support 4 (S4) 23.94